You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Les traitements par chimiothérapie et autres traitements systémiques pourraient être modifiés en raison de la COVID-19. Vous trouverez de plus amples renseignements à la page Traitements systémiques pendant la pandémie de la COVID-19.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

15 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Aug 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Palliative
Drugs Used:
enasidenib (Unfunded)
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB Limited Use
    exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
Jun 2019
Cancer Type: Breast     
Intent: Adjuvant
Funding:
ODB Limited Use
    exemestane - Sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    exemestane - Hormonal treatment of metastatic breast cancer in hormone receptor positive postmenopausal women who have disease progression following tamoxifen therapy
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced breast cancer or metastatic breast cancer, according to clinical criteria
Drugs Used:
exemestane (Unfunded),
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of breast cancer according to clinical criteria
Drugs Used:
exemestane (Unfunded),
Sep 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Sep 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
New Drug Funding Program
    Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sep 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant
Drugs Used:
pembrolizumab (Unfunded)
Dec 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
pembrolizumab (Unfunded)
Nov 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Palliative
Drugs Used:
pembrolizumab (Unfunded)
Nov 2019